Press Room

RDD 2024

Sunday, May 05, 2024
Thursday, May 09, 2024
Location: Arizona, United States
Booth Number: 22
RDD 2024 - Hovione

Hovione will be exhibiting at RDD conference from May 5-9. Don’t miss the chance to speak with our experts and learn how our development and manufacturing services for inhalation and nasal - integrated on a single site - can support in bringing your product to market.
We are centrally located between the 'Inspiring Dry Powder Inhalation' and 'Nasal Spotlight' Knowledge Space areas.

schedule a meeting





Nasal Powders: Enhancing Formulation and Device Synergy
May 7th from 2:00 PM to 6:00 PM 
Dina Morais, Ph.D. - R&D Senior Scientist, Inhalation and Advanced Drug Delivery
Cláudia Costa, Ph.D. - R&D Scientist, Advanced Analytical Characterization

Access the recorded session here

(Gated content. Registration is required.)


Short description: This workshop will address the complexities of formulating nasal powders including achieving the right balance between drug solubility, bioavailability, and delivery by exploring Hovione´s nasal toolbox for formulation strategies and advanced analytical characterization, within the current regulatory framework. The selection of appropriate excipients and manufacturing technologies as well as control over critical process parameters are key factors during product development. The formulation-device dependency when developing nasal products will also be highlighted, focusing on case studies using the new Hovione nasal device.

Key learning: Get to know Hovione´s integrated formulation-device solution for nasal powders development and learn how the early-stage in vitro screening may be predictive of the in vivo nasal powder performance.


"Systemic Nasal Absorption of Amorphous Solid Dispersions: Supersaturating Systems for Fast Onset of Action of Poorly Soluble Drugs Through the Nasal Mucosa"
Patricia Henriques, Dina Morais, Slavomíra Doktorovová, Ana Fortuna
Presenter: Dina Morais, Ph.D. - R&D Senior Scientist, Inhalation and Advanced Drug Delivery

Poster brief description: The poster shows the potential of amorphous solid dispersions for nasal delivery of a poorly soluble drug, through in vitro, ex vivo and in vivo studies.

Key Learning: Supersaturating systems promote nasal absorption of poorly soluble drugs, leading to faster onset of action. In vitro dissolution and ex vivo permeation methodologies are valuable tools for selecting the best formulations prototypes.


"Drug Load Influence on Aerodynamic Properties of High Dosage DPIs: A Case Study of an Aminoglycoside Model Drug"
João Pires, Maria Inês Lopes
Presenter: João Pires, Ph.D. - R&D Manager, Inhalation and Advanced Drug Development

Brief description: The study assessed the influence of the drug load on both primary aerodynamic distributions, measured online in the spray-drying process, and the final in vitro performance of carrier-free DPI formulations.
Key Learning: The aerodynamic size measurement during the spray-drying process allows the rapid screening of viable formulation candidates, enabling a more straightforward DPI development process.


"Differential Permeability of Dry Solid and Aqueous Suspensions of Fluticasone Propionate through A549 Alveolar Epithelial Cells"
Alexandre J.S. Ribeiro
Presenter: Alexandre Ribeiro, Ph.D. - R&D Principal Analytical Scientist, Analytical Development

Short description: Determining the lung permeability of orally inhaled drug products with in vitro cell-based platforms has high potential to predict their bioavailability during preclinical studies and increase the success rate of drug development. Cellular platforms used in permeability studies aim to recreate the pulmonary epithelial air-liquid interface barrier, where an inhalable product is deposited onto its apical side and then permeated through a polarized and tight epithelium into its basolateral side. A dry powder fluticasone propionate inhalable formulation was deposited in powder form or suspended in a cellular buffer solution on the apical side of an epithelial culture to investigate differences in permeability related with these different approaches for delivering inhalable formulations onto epithelial air-liquid interfaces.  

Key learning: By investigating optimal conditions to estimate the permeability of inhalable products, Hovione is establishing standards for improving formulation screening with these techniques in the early phases of drug development. 


"Understanding Leucine Encapsulation in Dry Powder Inhaler Microparticles via Surface Characterization Techniques"
Lídia Santos, Cláudia Costa
Presenter: Cláudia Costa, Ph.D. - R&D Scientist, Advanced Analytical Characterization

Poster brief description: Encapsulation in the DPI formulations were evaluated using specified surface characterization techniques, XPS, IGC and SEM. For XPS analysis the sample preparation and method conditions were previously assessed to assure repeatable and accurate results. The combination of the 3 techniques revealed good insights into the surface composition, shape, and structure of the composite particles. The differences in solubility and molecular structure of the APIs enabled a better understanding of the encapsulation behavior of leucine.

Key Learning: Deep lung delivery of DPI formulations is highly impacted by the cohesion forces between particles. An extensive characterization of the encapsulation process is imperative to achieve a reproducible and repeatable process with good aerosolization performance.



Title: High-dose Delivery Platform For Crystalline DPIs
Authors: Susana Saldanha, Lídia Santos, Rui Churro
Source: OnDrugDelivery, 23 April 2024

Abstract: Respiratory drug delivery has diversified the pipeline and portfolio of diseases that can be treated through this route, including already approved anti-infective medicines for cystic fibrosis or influenza patients, and others in development for pulmonary arterial hypertension, idiopathic pulmonary fibrosis and other rare lung diseases. Also, the doses and molecules delivered to the lungs have increased in the last years from a few micrograms to milligrams. This growth in the delivery of high doses has been observed in pharmaceutical compounds, such as antibiotics, vaccines, proteins and peptides, as well as for the treatment of acute emergency indications via the inhalation route.

Read the full article here 


Schedule a meeting with our team and get to know more about our unique range of particle engineering technologies for Inhalation & Nasal such as jet milling, wet milling and spray drying.


Let’s discuss your project together.

schedule a meeting


Find more about RDD2024


Also in the Press Room

See All